Review Article | Published:

Synthetic materials at the forefront of gene delivery

Nature Reviews Chemistryvolume 2pages258277 (2018) | Download Citation

Abstract

The delivery of nucleic acids with transient activity for genetic engineering is a promising methodology with potential applications in the treatment of diseases ranging from cancer and infectious diseases to heritable disorders. Restoring the expression of a missing protein, correcting defective splicing of transcripts and silencing or modulating the expression of genes are powerful approaches that could have substantial benefits in biological research and medicine. Impressive progress in improving gene delivery has been made in the past decade, and several products have reached the market. However, translating the results of in vitro and preclinical studies into functional therapies is hindered by the suboptimal performance of gene delivery vehicles in capturing, protecting and delivering nucleic acid cargoes safely and efficaciously. Chemistry has a key role in the development of innovative synthetic materials to overcome the challenges of producing next-generation gene delivery therapies and protocols. In this Review, we discuss the latest chemical advances in the production of materials for the delivery of nucleic acids to cells and for gene therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Matteucci, M. D. & Caruthers, M. H. Synthesis of deoxyoligonucleotides on a polymer support. J. Am. Chem. Soc. 103, 3185–3191 (1981).

  2. 2.

    Saiki, R. K. et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239, 487–491 (1988).

  3. 3.

    Hutchison, C. A. et al. Mutagenesis at a specific position in a DNA sequence. J. Biol. Chem. 253, 6551–6560 (1978).

  4. 4.

    Heim, R. & Tsien, R. Y. Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer. Curr. Biol. 6, 178–182 (1996).

  5. 5.

    Barbas, C. F., Kang, A. S., Lerner, R. A. & Benkovic, S. J. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc. Natl Acad. Sci. USA 88, 7978–7982 (1991).

  6. 6.

    Wang, L., Brock, A., Herberich, B. & Schultz, P. G. Expanding the genetic code of Escherichia coli. Science 292, 498–500 (2001).

  7. 7.

    Lerner, R. A., Benkovic, S. J. & Schultz, P. G. At the crossroads of chemistry and immunology: catalytic antibodies. Science 252, 659–667 (1991).

  8. 8.

    Siegel, J. B. et al. Computational design of an enzyme catalyst for a stereoselective bimolecular Diels-Alder reaction. Science 329, 309–313 (2010).

  9. 9.

    Wang, L. et al. Synthetic genomics: from DNA synthesis to genome design. Angew. Chem. Int. Ed. 57, 1748–1756 (2018).

  10. 10.

    Gibson, D. G. et al. Creation of a bacterial cell controlled by a chemically synthesized genome. Science 329, 52–56 (2010).

  11. 11.

    Annaluru, N. et al. Total synthesis of a functional designer eukaryotic chromosome. Science 344, 55–58 (2014).

  12. 12.

    Naldini, L. Gene therapy returns to centre stage. Nature 526, 351–360 (2015).

  13. 13.

    Dunbar, C. E. et al. Gene therapy comes of age. Science 359, eaan4672 (2018).

  14. 14.

    Sheridan, C. Gene therapy finds its niche. Nat. Biotechnol. 29, 121–128 (2011).

  15. 15.

    Jenks, S. Gene therapy death—“everyone has to share in the guilt”. J. Natl Cancer Inst. 92, 98–100 (2000).

  16. 16.

    Wang, T., Upponi, J. R. & Torchilin, V. P. Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int. J. Pharm. 427, 3–20 (2012).

  17. 17.

    Juliano, R. L. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 44, 6518–6548 (2016).

  18. 18.

    Yin, H. et al. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541–555 (2014).

  19. 19.

    Hill, A. B., Chen, M., Chen, C. K., Pfeifer, B. A. & Jones, C. H. Overcoming gene-delivery hurdles: physiological considerations for nonviral vectors. Trends Biotechnol. 34, 91–105 (2016).

  20. 20.

    Giacca, M. & Zacchigna, S. Virus-mediated gene delivery for human gene therapy. J. Control. Release 161, 377–388 (2012).

  21. 21.

    Merten, O. W. & Gaillet, B. Viral vectors for gene therapy and gene modification approaches. Biochem. Eng. J. 108, 98–115 (2016).

  22. 22.

    Melchiorri, D. et al. Regulatory evaluation of Glybera in Europe — two committees, one mission. Nat. Rev. Drug Discov. 12, 719 (2013).

  23. 23.

    Peng, Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16, 1016–1027 (2005).

  24. 24.

    Russell, S. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390, 849–860 (2017).

  25. 25.

    Kaiser, J. A second chance. Science 358, 582–585 (2017).

  26. 26.

    Senior, M. After Glybera’s withdrawal, what’s next for gene therapy? Nat. Biotechnol. 35, 491–492 (2017).

  27. 27.

    Hajj, K. A. & Whitehead, K. A. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat. Rev. Mater. 2, 17056 (2017).

  28. 28.

    Kaczmarek, J. C., Kowalski, P. S. & Anderson, D. G. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 9, 60 (2017).

  29. 29.

    Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R. & Blankschtein, D. mRNA vaccine delivery using lipid nanoparticles. Ther. Deliv. 7, 319–334 (2016).

  30. 30.

    Stanton, M. G. Current status of messenger RNA delivery systems. Nucleic Acid. Ther. 28, 158–165 (2018).

  31. 31.

    Hartung, T. & Daston, G. Are in vitro tests suitable for regulatory use? Toxicol. Sci. 111, 233–237 (2009).

  32. 32.

    Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238–248 (2017). This review provides a comprehensive overview of the chemical modifications of oligonucleotides of medical interest.

  33. 33.

    Kumar, S. R., Markusic, D. M., Biswas, M., High, K. A. & Herzog, R. W. Clinical development of gene therapy: results and lessons from recent successes. Mol. Ther. Methods Clin. Dev. 3, 16034 (2016).

  34. 34.

    Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M. & Abedi, M. R. Gene therapy clinical trials worldwide to 2017: an update. J. Gene Med. 20, e3015 (2018).

  35. 35.

    Stein, C. A. & Castanotto, D. FDA-approved oligonucleotide therapies in 2017. Mol. Ther. 25, 1069–1075 (2017).

  36. 36.

    Zuckerman, J. E. & Davis, M. E. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat. Rev. Drug Discov. 14, 843–856 (2015).

  37. 37.

    Barata, P., Sood, A. K. & Hong, D. S. RNA-targeted therapeutics in cancer clinical trials: current status and future directions. Cancer Treat. Rev. 50, 35–47 (2016).

  38. 38.

    Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11–21 (2018).

  39. 39.

    Stein, C. A. et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 38, e3 (2010).

  40. 40.

    Goyenvalle, A. et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat. Med. 21, 270–275 (2015).

  41. 41.

    Geary, R. S., Baker, B. F. & Crooke, S. T. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (Kynamro®): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin. Pharmacokinet. 54, 133–146 (2015).

  42. 42.

    Souleimanian, N. et al. Antisense 2ʹ-deoxy, 2ʹ-fluoroarabino nucleic acid (2’F-ANA) oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids. Mol. Ther. Nucleic Acids 1, e43 (2012).

  43. 43.

    Azad, R. F., Brown-Driver, V., Buckheit, R. W. & Anderson, K. P. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antiviral Res. 28, 101–111 (1995).

  44. 44.

    Chi, X., Gatti, P. & Papoian, T. Safety of antisense oligonucleotide and siRNA-based therapeutics. Drug Discov. Today 22, 823–833 (2017).

  45. 45.

    Shen, W. et al. Acute hepatotoxicity of 2ʹ fluoro-modified 5–10–5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins. Nucleic Acids Res. 46, 2204–2217 (2018).

  46. 46.

    Burdick, A. D. et al. Sequence motifs associated with hepatotoxicity of locked nucleic acid — modified antisense oligonucleotides. Nucleic Acids Res. 42, 4882–4891 (2014).

  47. 47.

    Fuertes, A., Juanes, M., Granja, J. R. & Montenegro, J. Supramolecular functional assemblies: dynamic membrane transporters and peptide nanotubular composites. Chem. Commun. 53, 7861–7871 (2017).

  48. 48.

    Meade, B. R. et al. Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat. Biotechnol. 32, 1256–1261 (2014). This study presents a method for the efficient production of phosphotriester nucleic acid derivatives that have excellent targeting and delivery properties.

  49. 49.

    McNamara, J. O. et al. Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005–1015 (2006).

  50. 50.

    Shu, D. et al. Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano 9, 9731–9740 (2015).

  51. 51.

    Ren, K. et al. A DNA dual lock-and-key strategy for cell-subtype-specific siRNA delivery. Nat. Commun. 7, 13580 (2016).

  52. 52.

    Schmidt, K. et al. Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor. Nucleic Acids Res. 45, 2294–2306 (2017).

  53. 53.

    Tanowitz, M. et al. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes. Nucleic Acids Res. 45, 12388–12400 (2017).

  54. 54.

    Zlatev, I. et al. Reversal of siRNA-mediated gene silencing in vivo. Nat. Biotechnol. 36, 509–511 (2018).

  55. 55.

    Huang, Y. Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol. Ther. Nucleic Acids 6, 116–132 (2017).

  56. 56.

    Lu, X. et al. Effective antisense gene regulation via noncationic, polyethylene glycol brushes. J. Am. Chem. Soc. 138, 9097–9100 (2016).

  57. 57.

    Jia, F. et al. Depth-profiling the nuclease stability and the gene silencing efficacy of brush-architectured poly(ethylene glycol)–DNA conjugates. J. Am. Chem. Soc. 139, 10605–10608 (2017).

  58. 58.

    Jin, Y. et al. Biodegradable, multifunctional DNAzyme nanoflowers for enhanced cancer therapy. NPG Asia Mater. 9, e365 (2017).

  59. 59.

    Lee, J. H. et al. Rolling circle transcription-based polymeric siRNA nanoparticles for tumor-targeted delivery. J. Control. Release 263, 29–38 (2017).

  60. 60.

    Rozema, D. B. et al. Protease-triggered siRNA delivery vehicles. J. Control. Release 209, 57–66 (2015).

  61. 61.

    Lee, K. et al. In vivo delivery of transcription factors with multifunctional oligonucleotides. Nat. Mater. 14, 701–706 (2015). This paper presents a procedure for the delivery of transcription factors in vivo using oligonucleotides that are modified with pH-responsive constructs.

  62. 62.

    McCaffrey, J., Donnelly, R. F. & McCarthy, H. O. Microneedles: an innovative platform for gene delivery. Drug Deliv. Transl Res. 5, 424–437 (2015).

  63. 63.

    Suda, T. & Liu, D. Hydrodynamic gene delivery: its principles and applications. Mol. Ther. 15, 2063–2069 (2007).

  64. 64.

    Stewart, M. P. et al. In vitro and ex vivo strategies for intracellular delivery. Nature 538, 183–192 (2016).

  65. 65.

    Jackson, H. J., Rafiq, S. & Brentjens, R. J. Driving CAR T cells forward. Nat. Rev. Clin. Oncol. 13, 370–383 (2016).

  66. 66.

    Ding, X. et al. High-throughput nuclear delivery and rapid expression of DNA via mechanical and electrical cell-membrane disruption. Nat. Biomed. Eng. 1, 0039 (2017).

  67. 67.

    Chiappini, C. et al. Biodegradable silicon nanoneedles delivering nucleic acids intracellularly induce localized in vivo neovascularization. Nat. Mater. 14, 532–539 (2015).

  68. 68.

    Anderson, C. D., Moisyadi, S., Avelar, A., Walton, C. B. & Shohet, R. V. Ultrasound-targeted hepatic delivery of factor IX in hemophiliac mice. Gene Ther. 23, 510–519 (2016).

  69. 69.

    Manta, S. et al. Cationic microbubbles and antibiotic-free miniplasmid for sustained ultrasound–mediated transgene expression in liver. J. Control. Release 262, 170–181 (2017).

  70. 70.

    Chertok, B., Langer, R. S. & Anderson, D. G. Spatial control of gene expression by nanocarriers using heparin masking and ultrasound-targeted microbubble destruction. ACS Nano 10, 7267–7278 (2016).

  71. 71.

    Yoon, S., Wang, P., Peng, Q., Wang, Y. & Shung, K. K. Acoustic-transfection for genomic manipulation of single-cells using high frequency ultrasound. Sci. Rep. 7, 5275 (2017).

  72. 72.

    Pastuzyn, E. D. et al. The neuronal gene Arc encodes a repurposed retrotransposon Gag protein that mediates intercellular RNA transfer. Cell 172, 275 (2018).

  73. 73.

    Chen, L. S. et al. Efficient gene transfer using the human JC virus-like particle that inhibits human colon adenocarcinoma growth in a nude mouse model. Gene Ther. 17, 1033–1041 (2010).

  74. 74.

    Lee, P. W. et al. Polymer structure and conformation alter the antigenicity of virus-like particle-polymer conjugates. J. Am. Chem. Soc. 139, 3312–3315 (2017).

  75. 75.

    Zackova Suchanova, J., Neburkova, J., Spanielova, H., Forstova, J. & Cigler, P. Retargeting polyomavirus-like particles to cancer cells by chemical modification of capsid surface. Bioconjug. Chem. 28, 307–313 (2017).

  76. 76.

    Tong, G. J., Hsiao, S. C., Carrico, Z. M. & Francis, M. B. Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J. Am. Chem. Soc. 131, 11174–11178 (2009).

  77. 77.

    Eguchi, A. et al. Efficient siRNA delivery into primary cells by peptide transduction domain-dsRNA binding domain (PTD-DRBD) fusion protein. Nat. Biotechnol. 27, 567–571 (2009).

  78. 78.

    Yang, N. J. et al. Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins. Nucleic Acids Res. 45, 7602–7614 (2017).

  79. 79.

    Bienk, K. et al. An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing. J. Control. Release 232, 143–151 (2016).

  80. 80.

    Sarett, S. M. et al. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing. Proc. Natl Acad. Sci. USA 114, E6490–E6497 (2017).

  81. 81.

    Hvam, M. L. et al. Fatty acid-modified gapmer antisense oligonucleotide and serum albumin constructs for pharmacokinetic modulation. Mol. Ther. 25, 1710–1717 (2017).

  82. 82.

    Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709–717 (2005).

  83. 83.

    Cuellar, T. L. et al. Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res. 43, 1189–1203 (2015).

  84. 84.

    Lehto, T., Ezzat, K., Wood, M. J. A. & El Andaloussi, S. Peptides for nucleic acid delivery. Adv. Drug Deliv. Rev. 106, 172–182 (2016).

  85. 85.

    Tai, W. & Gao, X. Functional peptides for siRNA delivery. Adv. Drug Deliv. Rev. 110–111, 157–168 (2017).

  86. 86.

    Hammond, S. M. et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc. Natl Acad. Sci. USA 113, 10962–10967 (2016).

  87. 87.

    Echigoya, Y. et al. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc. Natl Acad. Sci. USA 114, 4213–4218 (2017).

  88. 88.

    Medina, S. H. et al. An intrinsically disordered peptide facilitates non-endosomal cell entry. Angew. Chem. Int. Ed. 55, 3369–3372 (2016).

  89. 89.

    Soudah, T., Mogilevsky, M., Karni, R. & Yavin, E. CLIP6-PNA-peptide conjugates: non-endosomal delivery of splice switching oligonucleotides. Bioconjug. Chem. 28, 3036–3042 (2017).

  90. 90.

    Bulut, S. et al. Slow release and delivery of antisense oligonucleotide drug by self-assembled peptide amphiphile nanofibers. Biomacromolecules 12, 3007–3014 (2011).

  91. 91.

    Mazza, M., Hadjidemetriou, M., de Lázaro, I., Bussy, C. & Kostarelos, K. Peptide nanofiber complexes with siRNA for deep brain gene silencing by stereotactic neurosurgery. ACS Nano 9, 1137–1149 (2015).

  92. 92.

    Yolamanova, M. et al. Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses. Nat. Nanotechnol. 8, 130–136 (2013).

  93. 93.

    Dai, B. et al. Tunable assembly of amyloid-forming peptides into nanosheets as a retrovirus carrier. Proc. Natl Acad. Sci. USA 112, 2996–3001 (2015).

  94. 94.

    McCarthy, H. O. et al. Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery. J. Control. Release 189, 141–149 (2014).

  95. 95.

    Udhayakumar, V. K. et al. Arginine-rich peptide-based mRNA nanocomplexes efficiently instigate cytotoxic T cell immunity dependent on the amphipathic organization of the peptide. Adv. Healthc. Mater. 6, 1601412 (2017).

  96. 96.

    Douat, C. et al. A cell-penetrating foldamer with a bioreducible linkage for intracellular delivery of DNA. Angew. Chem. Int. Ed. 54, 11133–11137 (2015).

  97. 97.

    Gehin, C. et al. Dynamic amphiphile libraries to screen for the “fragrant” delivery of siRNA into HeLa cells and human primary fibroblasts. J. Am. Chem. Soc. 135, 9295–9298 (2013).

  98. 98.

    Louzao, I., García-Fandiño, R. & Montenegro, J. Hydrazone-modulated peptides for efficient gene transfection. J. Mater. Chem. B 5, 4426–4434 (2017).

  99. 99.

    Lostalé-Seijo, I., Louzao, I., Juanes, M. & Montenegro, J. Peptide/Cas9 nanostructures for ribonucleoprotein cell membrane transport and gene edition. Chem. Sci. 8, 7923–7931 (2017).

  100. 100.

    Li, M. et al. Incorporation of a non-natural arginine analogue into a cyclic peptide leads to formation of positively charged nanofibers capable of gene transfection. Angew. Chem. Int. Ed. 55, 598–601 (2016).

  101. 101.

    Li, M., Schlesiger, S., Knauer, S. K. & Schmuck, C. A tailor-made specific anion-binding motif in the side chain transforms a tetrapeptide into an efficient vector for gene delivery. Angew. Chem. Int. Ed. 54, 2941–2944 (2015). This article introduces the new guanidiniocarbonyl pyrrole group for nucleic acid delivery.

  102. 102.

    Montenegro, J., Ghadiri, M. R. & Granja, J. R. Ion channel models based on self-assembling cyclic peptide nanotubes. Acc. Chem. Res. 46, 2955–2965 (2013).

  103. 103.

    Jana, P. et al. Efficient gene transfection through inhibition of β-sheet (amyloid fiber) formation of a short amphiphilic peptide by gold nanoparticles. Angew. Chem. Int. Ed. 56, 8083–8088 (2017).

  104. 104.

    Freire, J. M. et al. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model. J. Control. Release 245, 127–136 (2017).

  105. 105.

    Felgner, P. L. et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA 84, 7413–7417 (1987).

  106. 106.

    Allen, T. M. & Cullis, P. R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36–48 (2013).

  107. 107.

    Oude Blenke, E. E., van den Dikkenberg, J., van Kolck, B., Kros, A. & Mastrobattista, E. Coiled coil interactions for the targeting of liposomes for nucleic acid delivery. Nanoscale 8, 8955–8965 (2016).

  108. 108.

    Yang, J. et al. Drug delivery via cell membrane fusion using lipopeptide modified liposomes. ACS Cent. Sci. 2, 621–630 (2016).

  109. 109.

    O’Brien, P. J., Elahipanah, S., Rogozhnikov, D. & Yousaf, M. N. Bio-orthogonal mediated nucleic acid transfection of cells via cell surface engineering. ACS Cent. Sci. 3, 489–500 (2017). This study describes a method for the application of bioorthogonal chemistry to the fusion of liposomes.

  110. 110.

    Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 15, 7300–7306 (2015).

  111. 111.

    Farhood, H., Serbina, N. & Huang, L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta 1235, 289–295 (1995).

  112. 112.

    Leal, C., Bouxsein, N. F., Ewert, K. K. & Safinya, C. R. Highly efficient gene silencing activity of siRNA embedded in a nanostructured gyroid cubic lipid matrix. J. Am. Chem. Soc. 132, 16841–16847 (2010).

  113. 113.

    Kim, H. & Leal, C. Cuboplexes: topologically active siRNA delivery. ACS Nano 9, 10214–10226 (2015).

  114. 114.

    Evers, M. J. W. et al. State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods. https://doi.org/10.1002/smtd.201700375 (2018).

  115. 115.

    Whitehead, K. A. et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 5, 4277 (2014).

  116. 116.

    Viricel, W. et al. Cationic switchable lipids: pH-triggered molecular switch for siRNA delivery. Nanoscale 9, 31–36 (2017).

  117. 117.

    Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401 (2016).

  118. 118.

    Oberli, M. A. et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 17, 1326–1335 (2017).

  119. 119.

    Liang, C. et al. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference–based bone anabolic strategy. Nat. Med. 21, 288–294 (2015).

  120. 120.

    Ripoll, M. et al. pH-responsive nanometric polydiacetylenic micelles allow for efficient intracellular siRNA delivery. ACS Appl. Mater. Interfaces 8, 30665–30670 (2016).

  121. 121.

    Morin, E., Nothisen, M., Wagner, A. & Remy, J. S. Cationic polydiacetylene micelles for gene delivery. Bioconjug. Chem. 22, 1916–1923 (2011).

  122. 122.

    Neuberg, P. et al. Polydiacetylenic nanofibers as new siRNA vehicles for in vitro and in vivo delivery. Nanoscale 10, 1587–1590 (2018).

  123. 123.

    Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. 51, 8529–8533 (2012).

  124. 124.

    Yim, N. et al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein–protein interaction module. Nat. Commun. 7, 12277 (2016).

  125. 125.

    Lee, J. et al. Cellular engineering with membrane fusogenic liposomes to produce functionalized extracellular vesicles. ACS Appl. Mater. Interfaces 8, 6790–6795 (2016). This study describes a versatile method for the chemical functionalization of exosomes.

  126. 126.

    O’Loughlin, A. J. et al. Functional delivery of lipid-conjugated siRNA by extracellular vesicles. Mol. Ther. 25, 1580–1587 (2017).

  127. 127.

    Didiot, M. C. et al. Exosome-mediated delivery of hydrophobically modified siRNA for Huntingtin mRNA silencing. Mol. Ther. 24, 1836–1847 (2016).

  128. 128.

    Cui, Z. K. et al. Delivery of siRNA via cationic sterosomes to enhance osteogenic differentiation of mesenchymal stem cells. J. Control. Release 217, 42–52 (2015).

  129. 129.

    Wang, Y. et al. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat. Mater. 13, 204–212 (2014).

  130. 130.

    Xu, X. et al. Ultra-pH-responsive and tumor-penetrating nanoplatform for targeted siRNA delivery with robust anti-cancer efficacy. Angew. Chem. Int. Ed. 55, 7091–7094 (2016).

  131. 131.

    Xu, X. et al. Multifunctional envelope-type siRNA delivery nanoparticle platform for prostate cancer therapy. ACS Nano 11, 2618–2627 (2017).

  132. 132.

    Zhou, J. et al. pH-sensitive nanomicelles for high-efficiency siRNA delivery in vitro and in vivo: an insight into the design of polycations with robust cytosolic release. Nano Lett. 16, 6916–6923 (2016). This article focuses on the properties of polycations that are required to maximize cytosolic release of siRNA cargoes in conditions of very low uptake.

  133. 133.

    Chiper, M., Tounsi, N., Kole, R., Kichler, A. & Zuber, G. Self-aggregating 1.8 kDa polyethylenimines with dissolution switch at endosomal acidic pH are delivery carriers for plasmid DNA, mRNA, siRNA and exon-skipping oligonucleotides. J. Control. Release 246, 60–70 (2017).

  134. 134.

    Cheng, Y., Yumul, R. C. & Pun, S. H. Virus-inspired polymer for efficient in vitro and in vivo gene delivery. Angew. Chem. Int. Ed. 55, 12013–12017 (2016).

  135. 135.

    Cheng, Y. et al. Development of switchable polymers to address the dilemma of stability and cargo release in polycationic nucleic acid carriers. Biomaterials 127, 89–96 (2017).

  136. 136.

    McKinlay, C. J. et al. Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc. Natl Acad. Sci. USA 114, E448–E456 (2017). This study describes a self-immolative polymer that can deliver mRNA in primary cells and in vivo.

  137. 137.

    Chahal, J. S. et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl Acad. Sci. USA 113, E4133–E4142 (2016).

  138. 138.

    Liu, S. et al. Bioreducible zinc(ii)-coordinative polyethylenimine with low molecular weight for robust gene delivery of primary and stem cells. J. Am. Chem. Soc. 139, 5102–5109 (2017).

  139. 139.

    Zou, Y. et al. Virus-mimicking chimaeric polymersomes boost targeted cancer siRNA therapy in vivo. Adv. Mater. 29, 1703285 (2017).

  140. 140.

    Li, L. et al. Artificial virus delivers CRISPR-Cas9 system for genome editing of cells in mice. ACS Nano 11, 95–111 (2017).

  141. 141.

    Naito, M. et al. A phenylboronate-functionalized polyion complex micelle for ATP-triggered release of siRNA. Angew. Chem. Int. Ed. 51, 10751–10755 (2012).

  142. 142.

    Naito, M. et al. Enhanced intracellular delivery of siRNA by controlling ATP-responsivity of phenylboronic acid-functionalized polyion complex micelles. Macromol. Biosci. 18, 1700357 (2018).

  143. 143.

    Yoshinaga, N. et al. Polyplex micelles with phenylboronate/gluconamide cross-linking in the core exerting promoted gene transfection through spatiotemporal responsivity to intracellular pH and ATP concentration. J. Am. Chem. Soc. 139, 18567–18575 (2017).

  144. 144.

    Truong, N. P. et al. An influenza virus-inspired polymer system for the timed release of siRNA. Nat. Commun. 4, 1902 (2013).

  145. 145.

    Wang, M., Liu, H., Li, L. & Cheng, Y. A fluorinated dendrimer achieves excellent gene transfection efficacy at extremely low nitrogen to phosphorus ratios. Nat. Commun. 5, 3053 (2014).

  146. 146.

    Wang, H. et al. Self-assembled fluorodendrimers combine the features of lipid and polymeric vectors in gene delivery. Angew. Chem. Int. Ed. 54, 11647–11651 (2015).

  147. 147.

    Wang, L. H., Wu, D. C., Xu, H. X. & You, Y. Z. High DNA-binding affinity and gene-transfection efficacy of bioreducible cationic nanomicelles with a fluorinated core. Angew. Chem. Int. Ed. 55, 755–759 (2016).

  148. 148.

    Zhang, Z. et al. The fluorination effect of fluoroamphiphiles in cytosolic protein delivery. Nat. Commun. 9, 1377 (2018).

  149. 149.

    Davis, M. E. The first targeted delivery of siRNA in humans via a nanoparticle: from concept to clinic. Mol. Pharm. 6, 659–668 (2009).

  150. 150.

    Maity, S., Choudhary, P., Manjunath, M., Kulkarni, A. & Murthy, N. A biodegradable adamantane polymer with ketal linkages in its backbone for gene therapy. Chem. Commun. 51, 15956–15959 (2015).

  151. 151.

    Chen, X., Qiu, Y. K., Owh, C., Loh, X. J. & Wu, Y. L. Supramolecular cyclodextrin nanocarriers for chemo- and gene therapy towards the effective treatment of drug resistant cancers. Nanoscale 8, 18876–18881 (2016).

  152. 152.

    Eldredge, A. C., Johnson, M. E., Oldenhuis, N. J. & Guan, Z. Focused library approach to discover discrete dipeptide bolaamphiphiles for siRNA delivery. Biomacromolecules 17, 3138–3144 (2016).

  153. 153.

    Yan, Y. et al. Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells. Proc. Natl Acad. Sci. USA 113, E5702–E5710 (2016).

  154. 154.

    Hao, J. et al. Rapid synthesis of a lipocationic polyester library via ring-opening polymerization of functional valerolactones for efficacious siRNA delivery. J. Am. Chem. Soc. 137, 9206–9209 (2015).

  155. 155.

    Priegue, J. M. et al. In situ functionalized polymers for siRNA delivery. Angew. Chem. Int. Ed. 55, 7492–7495 (2016).

  156. 156.

    Priegue, J. M. et al. Different-length hydrazone activated polymers for plasmid DNA condensation and cellular transfection. Biomacromolecules 19, 2638–2649 (2018).

  157. 157.

    Zhao, Y. et al. PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery. Nat. Commun. 7, 11822 (2016).

  158. 158.

    Lyu, Y. et al. Dendronized semiconducting polymer as photothermal nanocarrier for remote activation of gene expression. Angew. Chem. Int. Ed. 56, 9155–9159 (2017).

  159. 159.

    Tan, Z., Dhande, Y. K. & Reineke, T. M. Cell penetrating polymers containing guanidinium trigger apoptosis in human hepatocellular carcinoma cells unless conjugated to a targeting N-acetyl-galactosamine block. Bioconjug. Chem. 28, 2985–2997 (2017).

  160. 160.

    Liu, Y., Wenning, L., Lynch, M. & Reineke, T. M. New poly(D-glucaramidoamine)s induce DNA nanoparticle formation and efficient gene delivery into mammalian cells. J. Am. Chem. Soc. 126, 7422–7423 (2004).

  161. 161.

    Dong, Y. et al. Poly(glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo. Nano Lett. 16, 842–848 (2016).

  162. 162.

    Kaczmarek, J. C. et al. Polymer–lipid nanoparticles for systemic delivery of mRNA to the lungs. Angew. Chem. Int. Ed. 55, 13808–13812 (2016).

  163. 163.

    Li, J. et al. Structurally programmed assembly of translation initiation nanoplex for superior mRNA delivery. ACS Nano 11, 2531–2544 (2017).

  164. 164.

    Hong, C. A. et al. Dendrimeric siRNA for efficient gene silencing. Angew. Chem. Int. Ed. 54, 6740–6744 (2015).

  165. 165.

    Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813–820 (2017). This study describes a method for the in situ modification of T cells for cancer immunotherapy.

  166. 166.

    Graham, F. L. & van der Eb, A. J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52, 456–467 (1973).

  167. 167.

    Hong, G., Diao, S., Antaris, A. L. & Dai, H. Carbon nanomaterials for biological imaging and nanomedicinal therapy. Chem. Rev. 115, 10816–10906 (2015).

  168. 168.

    Pantarotto, D. et al. Functionalized carbon nanotubes for plasmid DNA gene delivery. Angew. Chem. Int. Ed. 43, 5242–5246 (2004).

  169. 169.

    Battigelli, A. et al. Ammonium and guanidinium dendron-carbon nanotubes by amidation and click chemistry and their use for siRNA delivery. Small 9, 3610–3619 (2013).

  170. 170.

    Kam, N. W., Liu, Z. & Dai, H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J. Am. Chem. Soc. 127, 12492–12493 (2005).

  171. 171.

    Wang, J. T. et al. The relationship between the diameter of chemically-functionalized multi-walled carbon nanotubes and their organ biodistribution profiles in vivo. Biomaterials 35, 9517–9528 (2014).

  172. 172.

    Cifuentes-Rius, A. et al. In vivo fate of carbon nanotubes with different physicochemical properties for gene delivery applications. ACS Appl. Mater. Interfaces 9, 11461–11471 (2017).

  173. 173.

    Munk, M. et al. Efficient delivery of DNA into bovine preimplantation embryos by multiwall carbon nanotubes. Sci. Rep. 6, 33588 (2016).

  174. 174.

    Maeda-Mamiya, R. et al. In vivo gene delivery by cationic tetraamino fullerene. Proc. Natl Acad. Sci. USA 107, 5339–5344 (2010).

  175. 175.

    Sigwalt, D. et al. Gene delivery with polycationic fullerene hexakis-adducts. Chem. Commun. 47, 4640–4642 (2011).

  176. 176.

    Wang, J. et al. Visible light-switched cytosol release of siRNA by amphiphilic fullerene derivative to enhance RNAi efficacy in vitro and in vivo. Acta Biomater. 59, 158–169 (2017).

  177. 177.

    Dowaidar, M., Abdelhamid, H. N., Hällbrink, M., Zou, X. & Langel, Ü. Graphene oxide nanosheets in complex with cell penetrating peptides for oligonucleotides delivery. Biochim. Biophys. Acta 1861, 2334–2341 (2017).

  178. 178.

    Chu, Z. et al. Rapid endosomal escape of prickly nanodiamonds: implications for gene delivery. Sci. Rep. 5, 11661 (2015).

  179. 179.

    Lim, D. G. et al. Polyamidoamine-decorated nanodiamonds as a hybrid gene delivery vector and siRNA structural characterization at the charged interfaces. ACS Appl. Mater. Interfaces 9, 31543–31556 (2017).

  180. 180.

    Zhang, X. Q. et al. Polymer-functionalized nanodiamond platforms as vehicles for gene delivery. ACS Nano 3, 2609–2616 (2009).

  181. 181.

    Chen, M. et al. Nanodiamond vectors functionalized with polyethylenimine for siRNA delivery. J. Phys. Chem. Lett. 1, 3167–3171 (2010).

  182. 182.

    Yi, Y. et al. Targeted systemic delivery of siRNA to cervical cancer model using cyclic RGD-installed unimer polyion complex-assembled gold nanoparticles. J. Control. Release 244, 247–256 (2016).

  183. 183.

    Conde, J., Oliva, N., Zhang, Y. & Artzi, N. Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. Nat. Mater. 15, 1128–1138 (2016).

  184. 184.

    Lei, Y. et al. Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer. Nat. Commun. 8, 15130 (2017).

  185. 185.

    Cutler, J. I., Auyeung, E. & Mirkin, C. A. Spherical nucleic acids. J. Am. Chem. Soc. 134, 1376–1391 (2012).

  186. 186.

    Randeria, P. S. et al. siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown. Proc. Natl Acad. Sci. USA 112, 5573–5578 (2015).

  187. 187.

    Sita, T. L. et al. Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo. Proc. Natl Acad. Sci. USA 114, 4129–4134 (2017).

  188. 188.

    Li, N. et al. Nuclear-targeted siRNA delivery for long-term gene silencing. Chem. Sci. 8, 2816–2822 (2017). This paper shows the effect that the subcellular distribution of the cargo has on the duration of the gene silencing.

  189. 189.

    Rouge, J. L. et al. Ribozyme–spherical nucleic acids. J. Am. Chem. Soc. 137, 10528–10531 (2015).

  190. 190.

    Ruan, W. et al. DNA nanoclew templated spherical nucleic acids for siRNA delivery. Chem. Commun. 54, 3609–3612 (2018).

  191. 191.

    Calabrese, C. M. et al. Biocompatible infinite-coordination-polymer nanoparticle-nucleic-acid conjugates for antisense gene regulation. Angew. Chem. Int. Ed. 54, 476–480 (2015).

  192. 192.

    Banga, R. J., Chernyak, N., Narayan, S. P., Nguyen, S. T. & Mirkin, C. A. Liposomal spherical nucleic acids. J. Am. Chem. Soc. 136, 9866–9869 (2014).

  193. 193.

    Li, H. et al. Molecular spherical nucleic acids. Proc. Natl Acad. Sci. USA 115, 4340–4344 (2018).

  194. 194.

    Möller, K. et al. Highly efficient siRNA delivery from core–shell mesoporous silica nanoparticles with multifunctional polymer caps. Nanoscale 8, 4007–4019 (2016).

  195. 195.

    Shen, J. et al. High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano 7, 9867–9880 (2013).

  196. 196.

    Kapilov-Buchman, Y., Lellouche, E., Michaeli, S. & Lellouche, J. P. Unique surface modification of silica nanoparticles with polyethylenimine (PEI) for siRNA delivery using cerium cation coordination chemistry. Bioconjug. Chem. 26, 880–889 (2015).

  197. 197.

    Shen, J. et al. Multi-step encapsulation of chemotherapy and gene silencing agents in functionalized mesoporous silica nanoparticles. Nanoscale 9, 5329–5341 (2017).

  198. 198.

    He, C., Lu, K., Liu, D. & Lin, W. Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells. J. Am. Chem. Soc. 136, 5181–5184 (2014).

  199. 199.

    Chen, Q. et al. Se/Ru-decorated porous metal-organic framework nanoparticles for the delivery of pooled siRNAs to reversing multidrug resistance in taxol-resistant breast cancer cells. ACS Appl. Mater. Interfaces 9, 6712–6724 (2017).

  200. 200.

    Thierry, A. R. et al. Characterization of liposome-mediated gene delivery: expression, stability and pharmacokinetics of plasmid DNA. Gene Ther. 4, 226–237 (1997).

  201. 201.

    Tsui, N. B., Ng, E. K. & Lo, Y. M. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin. Chem. 48, 1647–1653 (2002).

  202. 202.

    Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics — developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014).

  203. 203.

    Layzer, J. M. et al. In vivo activity of nuclease-resistant siRNAs. RNA 10, 766–771 (2004).

Download references

Acknowledgements

The group of J.M. was partially supported by the Spanish Agencia Estatal de Investigación (AEI) (CTQ2014-59646-R and SAF2017-89890-R), the Xunta de Galicia (ED431G/09, ED431C 2017/25 and 2016-AD031) and the European Regional Development Fund (ERDF). J.M. received a Ramón y Cajal grant (RYC-2013-13784), a European Research Council (ERC) Starting Investigator Grant (DYNAP-677786) and a Young Investigator Grant from the Human Frontier Science Research Program (RGY0066/2017). The authors apologize to all researchers whose work could not be mentioned owing to space constraints.

Author information

Affiliations

  1. Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, Spain

    • Irene Lostalé-Seijo
    •  & Javier Montenegro

Authors

  1. Search for Irene Lostalé-Seijo in:

  2. Search for Javier Montenegro in:

Contributions

The authors contributed equally to all aspects of the article.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Javier Montenegro.

Glossary

Gymnosis

Spontaneous uptake of single-stranded oligonucleotides that are stabilized with backbone modifications in the absence of any carrier or additive.

Aptamer

An oligonucleotide with a defined 3D structure, which binds specifically to a target molecule, such as a protein, with high affinity.

Rolling-circle amplification

An enzymatic method to obtain a long single-stranded DNA molecule, which contains many repeats of the target sequence, from a circular DNA template.

Rolling-circle transcription

An enzymatic method to obtain a long single-stranded RNA molecule, which contains many repeats of the target sequence, from a circular DNA template.

Chimeric antigen receptor

(CAR). A fusion protein comprising the signalling domain of the T cell receptor and an extracellular antigen-binding domain that is usually derived from an antibody, which promotes T cell activation in the presence of the desired antigen.

Neonatal Fc receptor

(FcRn). A receptor that is expressed in many tissues and that binds to serum albumin and to some types of antibodies in the slightly acidic conditions in the early endosome, returning them to the cell exterior and preventing their degradation in the late endosome or lysosome.

Alphavirus replicons

RNA molecules derived from the alphavirus genome, in which genes encoding proteins that are essential for viral replication have been substituted by a gene of interest but can still be replicated and transcribed by the viral RNA polymerase.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41570-018-0039-1